Potential Efficacy of Midazolam as Second-Line Treatment for Terminal Dyspnea in Patients with Cancer: Secondary Analysis of a Multicenter Prospective Cohort Study

Potential Efficacy of Midazolam as Second-Line Treatment for Terminal Dyspnea in Patients with Cancer: Secondary Analysis of a Multicenter Prospective Cohort Study

Introduction: Opioids are widely used as first-line treatment for dyspnea in terminally-ill patients with advanced cancer (terminal dyspnea), but the merit of second-line treatment for persistent terminal dyspnea despite opioid titration is not clear. Objectives: To explore whether the adjunctive us...

Full description

Saved in:
Bibliographic Details
Main Authors: Satoru Miwa, Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, Tatsuya Morita, Eriko Satomi
Format: Article
Language:English
Published: Mary Ann Liebert 2024-10-01
Series:Palliative Medicine Reports
Subjects:
cancer
midazolam
opioid
terminal dyspnea
Online Access:https://www.liebertpub.com/doi/10.1089/pmr.2023.0076
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.liebertpub.com/doi/10.1089/pmr.2023.0076

Similar Items